Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 405 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Advancing Cancer Research as a Married Couple: “Your Stories” Podcast December 18, 2020 No Survival Benefit for Adding Adjuvant Chemotherapy to Endocrine Therapy in... June 15, 2022 El cáncer en mi comunidad: Ampliar el acceso a las pruebas... September 1, 2020 Opinion: The Government should not be choosing between investing in staff... July 27, 2022 Load more HOT NEWS Evidence for the Utility of ctDNA Monitoring for Recurrence After CRC... Teacher Is Glad She Asked for More Testing After Mammogram Failed... Activity and Manageable Toxicity of Pembrolizumab in Some Rare and Ultrarare... EMA Recommends Granting a Conditional Marketing Authorisation for Idecabtagene Vicleucel
